Research Laboratories, Vaccine and Virus

Optimizing your ELISA Assays | BMG LABTECH

BMG Labtech

MARCH 11, 2024

1,2 Anton Schuurs and Bauke van Weemen at the research laboratories of NV Organon, Oss, the Netherlands developed a similar technique which was also published in 1971. ELISAs played a pivotal role in the early detection of the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).

Vaccine

Vaccine Molecular Biology Laboratories Virus

Accelerating Vaccine Development for the Novel Infectious Disease with Pseudoviruses

PerkinElmer

MAY 28, 2020

Time is of the essence when it comes to the development of a vaccine for the novel infectious disease in our current pandemic. The world has changed due to its impact – and the race to discover a vaccine is crucial for our return to normalcy.

Vaccine

Vaccine Disease Virus Small Molecule

Annaliesa Anderson, Ph.D., Will Lead Pfizer’s Vaccine Research & Development

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer. Pfizer Inc. Jansen, Ph.D., who will be retiring from Pfizer.

Vaccine

Vaccine Research Laboratories Doctors

Regeneron’s Antibody Cocktail Shows Success in Preventing COVID-19 in Phase 3 Study | 2021-01-26

The Pharma Data

JANUARY 26, 2021

In what looks like a breakthrough for COVID-19 treatments, Regeneron’s monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab) cut infection rates in half and provided full protection against symptomatic COVID-19, according to interim results from a phase 3 trial evaluating the treatment as a passive vaccine.

Vaccine

Vaccine Virus Research Laboratories Trials

Vir and GSK Team Up with Eli Lilly for Double Monoclonal Antibody Study

The Pharma Data

JANUARY 26, 2021

Pre-clinical data showed the antibody can neutralize the virus by binding to an epitope on SARS-CoV-2 shared with SARS-CoV-1. As the virus continues to evolve, we, along with Lilly and GSK, share the view that we should pursue all possibilities to help end the pandemic and maximize the number of lives that can be saved.

Virus

Virus Trials Nurses Research Laboratories

Genus plc Provides Update on Financial Performance for First Half of Fiscal 2021

The Pharma Data

JANUARY 17, 2021

Outlook The prevalence of COVID-19 across the globe has increased substantially since the trading update provided in November and Genus expects there will continue to be some challenges for our customers and employees for the remainder of our financial year, despite the prospect of better conditions as vaccines are being made available.

Research Laboratories

Research Laboratories Regulations Production Laboratories

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

The Pharma Data

APRIL 16, 2021

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Treatment

Treatment Hospitals Long-Term Care Facilities Virus

Lilly’s bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19

The Pharma Data

FEBRUARY 12, 2022

Lilly’s chief scientific and medical officer, and president of Lilly Research Laboratories. Pseudovirus and authentic virus testing demonstrate that bebtelovimab retains full neutralizing activity against Omicron – currently the predominant variant in the U.S. About BLAZE-4.

Treatment

Treatment Hospitals FDA Clinical Trials

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

The Pharma Data

NOVEMBER 9, 2020

. “The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D.,

Treatment

Treatment FDA Hospitals Long-Term Care Facilities

Codon Digest: Injected Gene Editors

Codon

APRIL 2, 2023

A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different research laboratories. mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 Nature Neuroscience. Read You love to see it! Andreano E. Nature Communications.

DNA

DNA RNA Engineering Licensing

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

JANUARY 26, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. have reached record highs. It was identified from a blood sample taken from one of the first U.S.

Hospitals

Hospitals Treatment Trials Long-Term Care Facilities

Raising Welfare for Lab Rodents

Codon

JULY 21, 2024

As the biotechnologist Alex Telford writes , “Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments.” Work towards improving animal welfare is ongoing and certainly not limited to research laboratories.

Research

Research Engineering Disease Science

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3.

The Pharma Data

SEPTEMBER 1, 2021

MOVe-AHEAD (MK-4482-013) ( NCT04939428 ) is a Phase 3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered molnupiravir compared to placebo in preventing the spread of SARS-CoV-2, the virus that causes COVID-19, within households. About Molnupiravir.

Laboratories

Laboratories Clinical Trials Virus Trials

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

The Pharma Data

JANUARY 24, 2021

(NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.

Vaccine

Vaccine Immune Response Virus Production

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

The Pharma Data

MARCH 11, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Hospitals

Hospitals Trials Long-Term Care Facilities Treatment

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

The Pharma Data

NOVEMBER 22, 2020

Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent. About Merck.

Trials

Trials Clinical Trials International Production

Drug Discovery Digest

Optimizing your ELISA Assays | BMG LABTECH

Accelerating Vaccine Development for the Novel Infectious Disease with Pseudoviruses

Trending Sources

Annaliesa Anderson, Ph.D., Will Lead Pfizer’s Vaccine Research & Development

Regeneron’s Antibody Cocktail Shows Success in Preventing COVID-19 in Phase 3 Study | 2021-01-26

Vir and GSK Team Up with Eli Lilly for Double Monoclonal Antibody Study

Genus plc Provides Update on Financial Performance for First Half of Fiscal 2021

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

Lilly’s bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

Codon Digest: Injected Gene Editors

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

Raising Welfare for Lab Rodents

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3.

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

Stay Connected